MPC values should be considered in drawing dosing strategies since traditional MIC-based dosing level might give rise to treatment failure due to the selection of drug-resistant mutant.
Although the in vivo PAE of enrofloxacin was still awaiting further investigation, our data at least suggested that the T>MPC seemed to be the dominant factor in drawing dose intervals since PAE of enrofloxacin was comparably short.
It was in 2000, Dr. Finkelstein told the investigators, that he began using one syringe to draw doses from numerous vials.
Based on integrated PK/PD parameters (AUC/MIC, Cmax/MIC, and T>MPC), the results of this study established a principle, for the first time, on drawing accurate dosing guideline for pharmacotherapy against A. hydrophila strain (AH10) for prevention of drug-resistant mutants.
Samples were drawn before dosing and then following the morning dose of olaparib at 30 min, 1, 2, 3, 4, 6, 8 and 12 h on day-7 and day 1 of cycle 1.
As shown in Figure 3A, two curves were drawn using dose-response datasets of wild-type and mutant cell lines.
Thus, serum PK/PD parameters were the major data that was based to draw a dosing guideline here (Table 6 and Figure 4).
Before definitive conclusions can be drawn about dose adjustment after ORTs, these results need to be confirmed in a large randomised controlled trial (RCT).
Samples were also drawn pre-dose and at 1 h, on Day 8 of Cycle 1 and Days 1, 8 and 15 of subsequent cycles.
For gemcitabine and dFdU PK profiles, blood samples were drawn pre-dose and up to 9 h after the start of infusion on cycle 1, days 1 and 22 (with sunitinib on Schedule 4/2) or on cycle 1, days 1 and 8 (with sunitinib on Schedule 2/1).
